Literature DB >> 20376653

[Adjustable systems for the treatment of male incontinence].

W A Hübner1.   

Abstract

The principle of adjustment with the possibility to react to changing needs of specific patients even years after placing an implant is convincing. Experience has taught that urodynamic parameters as well as personal demands of a patient may change individually for instance as a result of resuming physical activities. Such demands can be met by simple adjustment.Results of Argus and Remeex can be considered equally sustainable as first publications date back from 2006 and 2004. With follow-up periods of more than 2 years realistic success rates of up to 90% have been observed. Adjustment will be needed in one third of cases.The ProAct balloons are attractive by virtue of the low invasiveness of both implantation and adjustment. A series published in 2005 revealed a success rate of 77%; these experiences have been confirmed by several other papers. Limiting factors for ProAct are irradiation therapy and scarred bladder neck.

Entities:  

Mesh:

Year:  2010        PMID: 20376653     DOI: 10.1007/s00120-010-2260-5

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  8 in total

1.  Transrectal ultrasound guided implantation of the ProACT adjustable continence therapy system in patients with post-radical prostatectomy stress urinary incontinence: a pilot study.

Authors:  Andrea Gregori; Alchiede Simonato; Andrea Lissiani; Francesco Scieri; Roberta Rossi; Franco Gaboardi
Journal:  J Urol       Date:  2006-11       Impact factor: 7.450

2.  Adjustable suburethral sling (male remeex system) in the treatment of male stress urinary incontinence: a multicentric European study.

Authors:  Alejandro Sousa-Escandón; Javier Cabrera; Franco Mantovani; Marco Moretti; Evangelos Ioanidis; Nikolaos Kondelidis; Joerg Neymeyer; Rui Noguera
Journal:  Eur Urol       Date:  2007-06-04       Impact factor: 20.096

3.  Adjustable continence therapy (ProACT): evolution of the surgical technique and comparison of the original 50 patients with the most recent 50 patients at a single centre.

Authors:  Wilhelm A Hübner; Oliver M Schlarp
Journal:  Eur Urol       Date:  2006-11-03       Impact factor: 20.096

4.  Treatment of incontinence after prostatectomy using a new minimally invasive device: adjustable continence therapy.

Authors:  Wilhelm A Hübner; Oliver M Schlarp
Journal:  BJU Int       Date:  2005-09       Impact factor: 5.588

5.  An adjustable continence therapy device for treating incontinence after prostatectomy: a minimum 2-year follow-up.

Authors:  Peter J Gilling; Deborah F Bell; Liam C Wilson; Andre M Westenberg; Rana Reuther; Mark R Fraundorfer
Journal:  BJU Int       Date:  2008-10-08       Impact factor: 5.588

6.  Implantation of an adjustable continence therapy system using local anesthesia in patients with post-radical prostatectomy stress urinary incontinence: a pilot study.

Authors:  Andrea Gregori; Stefano Galli; Ioannis Goumas Kartalas; Francesco Scieri; Silvio Stener; Giacomo Piero Incarbone; Franco Gaboardi
Journal:  J Urol       Date:  2008-03-18       Impact factor: 7.450

7.  Externally readjustable sling for treatment of male stress urinary incontinence: points of technique and preliminary results.

Authors:  Alejandro Sousa-Escandón; José Ignacio Rodríguez Gómez; Carlos Uribarri González; Antonio Marqués-Queimadelos
Journal:  J Endourol       Date:  2004-02       Impact factor: 2.942

8.  An adjustable male sling for treating urinary incontinence after prostatectomy: a phase III multicentre trial.

Authors:  Salomon V Romano; Sergio E Metrebian; Fernando Vaz; Valter Muller; Carlos A D'Ancona; Eugenio A Costa DE Souza; Fabio Nakamura
Journal:  BJU Int       Date:  2006-03       Impact factor: 5.588

  8 in total
  1 in total

1.  Argus T® versus Advance® Sling for postprostatectomy urinary incontinence: A randomized clinical trial.

Authors:  Joao Paulo Cunha Lima; Antonio Carlos Lima Pompeo; Carlos Alberto Bezerra
Journal:  Int Braz J Urol       Date:  2016 May-Jun       Impact factor: 1.541

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.